Goodrx is trading 8.17% higher at $3.77, with the live rebound tracking a broad market rally; supplied context shows major indexes up more than 1.8%.
- Goodrx said its Q1 and Q2 2026 financial statements should no longer be relied upon because Pharma Direct revenue was understated.
- The company plans to restate the statements; the accounting announcement weighed on shares in premarket trading.